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Abstract
Background: Sporadic and sometimes contradictory studies have indicated changes in satellite
cell behaviour associated with the progressive nature of human Duchenne muscular dystrophy
(DMD). Satellite cell proliferation and number are reportedly altered in DMD and the mdx mouse
model. We recently found that satellite cells in MSVski transgenic mice, a muscle hypertrophy
model showing progressive muscle degeneration, display a severe ageing-related differentiation
defect in vitro. We tested the hypothesis that similar changes contribute to the gradual loss of
muscle function with age in mdx and PMP22 mice, a model of human motor and sensory neuropathy
type 1A (HMSN1A).
Methods: Single extensor digitorum longus muscle fibres were cultured from mdx and PMP22
mice and age- and genetic background-matched controls. Mice at several ages were compared with
regard to the differentiation of satellite cells, assayed as the proportion of desmin-expressing cells
that accumulated sarcomeric myosin heavy chain.
Results:  Satellite cells of 2 month, 6 month, and 12 month old mdx mice were capable of
differentiating to a similar extent to age-matched wild type control animals in an in vitro
proliferation/differentiation model. Strikingly, differentiation efficiency in individual 6 month and 12
month old mdx animals varies to a much higher extent than in age-matched controls, younger mdx
animals, or PMP22 mice. In contrast, differentiation of myoblasts from all myoD null mice assayed
was severely impaired in this assay system. The defect in satellite cell differentiation that occurs in
some mdx animals arises from a delay in differentiation that is not overcome by IGF-1 treatment at
any phase of cultivation.
Conclusion: Overall, a defect in satellite cell differentiation above that arising through normal
ageing does not occur in mdx or PMP22  mouse models of human disease. Nonetheless, the
impaired differentiation of satellite cells from some mdx animals suggests that additional factors,
environmental or epigenetic, may lead to deteriorating muscle repair through poor differentiation
of satellite cells in genetically predisposed individuals.
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Background
Like many muscle diseases, Duchenne muscular dystro-
phy (DMD) is characterised by a gradual loss of muscle
function with age. Patients are initially ambulatory and
have mild muscle pathology, despite ongoing degenera-
tion and repair. In later stages of DMD, patients experi-
ence progressively more severe muscular changes,
accompanied by loss of function, physical dependency,
and ultimately, death [1].
DMD patients generally lack the cytoskeletal protein dys-
trophin, a member of the spectrin-like superfamily of
actin binding proteins. Functional dystrophin is localised
to the inner face of the sarcolemma and binds to cytoskel-
etal F-actin and transmembrane beta-dystroglycan as part
of multiprotein complex that mediates signalling between
the cytoskeleton and the extracellular matrix. The conse-
quences of lack of dystrophin appear to be an enhanced
susceptibility to fibre damage and possibly poor signal-
ling between fibres and their environment. A milder form
of dystrophin deficiency in humans is the Becker-Kiener
type of muscular dystrophy (BMD). Here, dystrophin is
not completely absent, but mutations lead to a quantita-
tively and/or qualitatively reduced gene product which
does not accomplish its full function. The onset of BMD is
generally later than DMD. In childhood, symptoms are
usually very mild and muscle weakness becomes more
evident only in the teens or twenties. BMD is non-lethal
and patients often achieve normal life span, although the
disease can progress in later life [2].
To date, it is not clear what controls disease progression in
either DMD or BMD and no consensus has been reached
in the literature. The progressive loss of muscle in DMD
and other muscle disorders could be due to a sustained or
increasing rate of degeneration above the rate of repair, or
a progressive decline in the ability to regenerate the mus-
cle. Some pathological changes appear to be similar to
those observed in healthily ageing people, yet premature
and exacerbated. A popular, yet challenged view is that in
DMD, disease progression is attributable to accumulating
deficiencies in the ability of satellite cells resident within
the muscle to mediate regeneration and/or their own
replacement [3]. Satellite cell deficiencies could arise
because of the excessive demands on repair mechanisms
necessitated by the continuous degeneration of unstable
muscle that does not express dystrophin. Indeed, symp-
toms of rapid early turnover of muscle fibre material and
cells are apparent before birth in DMD patients [4], yet
serious functional deficits arise only late in the first
decade.
A commonly used model for studies of DMD is the mdx
mouse. These animals, like human patients, show delayed
onset of debilitating muscle degeneration. Although a
transient burst of frank degeneration occurs in mdx mice
during the period of muscle growth around the third post-
natal week, degeneration leading to debility only occurs
late in life, primarily in specific muscles, such as the dia-
phragm [5]. In mdx mice, as in human DMD patients, dis-
ease is caused by the absence of functional dystrophin,
owing to a nonsense mutation in exon 23. The relatively
mild phenotype of mdx mice can, in part, be attributed to
the compensatory function of the dystrophin-related pro-
tein utrophin, which is highly upregulated in regenerating
muscle fibres in adult mdx  mutants [6]. Over time,
enhanced muscle turnover and satellite cell numbers are
also seen in mdx mice [7].
Other muscle diseases also show variable clinical progres-
sion. Human motor and sensory neuropathy type 1A
(HMSN1A, also known as Charcot-Marie-Tooth disease
type 1A, CMT1A) is a dominantly inherited demyelinat-
ing disorder of the peripheral nervous system. It is most
frequently caused by over-expression of the PMP22 gene
due to duplication of a 1.5-Mb region on chromosome
17, but it can also result from point mutations in the
PMP22  gene [8-12]. The affected individuals typically
have distal muscle weakness and atrophy often associated
with mild to moderate sensory loss, depressed tendon
reflexes, and high-arched feet. Individuals with HMSN1A
experience slowly progressive weakness and atrophy of
distal muscles in the feet and/or hands. Disease progres-
sion is variable for unknown reasons.
PMP22 C22 transgenic mice which were modified to har-
bour seven copies of the human PMP22 gene demonstrate
developmental delays in myelination, decreased numbers
of myelinated fibres, and abnormally thin myelin similar
to HMSN1A [13]. Being a neuropathy, PMP22 C22 mice
can be used as reference animals that display a muscle
phenotype without harbouring intrinsic muscle defects.
In a recent study, we found that satellite cells of MSVski
transgenic mice display a differentiation defect compared
to wildtype control animals and that this defect is exacer-
bated in ageing animals [14]. Like mdx mice, hypertrophic
MSVski transgenic mouse muscles have muscle degenera-
tion that is initially efficiently repaired, but which eventu-
ally shows defective regeneration and frank muscle
defects. In the present paper, we investigate the differenti-
ation potential of satellite cells of single muscle fibres
from the hypertrophic mdx and PMP22 mouse models
and corresponding wildtype control animals in order to
clarify whether ageing-related change in differentiation
potential of satellite cells might influence disease
progression.BMC Musculoskeletal Disorders 2005, 6:15 http://www.biomedcentral.com/1471-2474/6/15
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Methods
Mouse strains
mdx mice were obtained from a colony in the lab of T. Par-
tridge (Imperial College, London, UK) and are similar to
JAX C57BL/10ScSn-Dmdmdx/J. Control mice were
obtained from JAX and were C57BL/10ScSn. MyoDm1 null
mice were as reported [15]. Mice were killed at ages of 6 to
8 weeks (referred to as 2 months), 22 to 25 weeks
(referred to as 6 months), or 44 to 55 weeks (referred to as
12 months). Mice of the HMSN1A model PMP22 C22
and the corresponding age matched litter mate controls
were received from the lab of C. Huxley at ages of 2 to 3
months (referred to as 2 months), 10 to 12 months
(referred to as 11 months), and 15 months. Mice were
kept in plastic cages with wire mesh lids in a 12:12-h light-
dark cycle and fed ad libitum. Both sexes were used for each
experimental time point to test for sex specific effects,
although none were observed, and at least 4 mice of each
genotype were used at each age. All animal experiments
were carried out in accordance with the local ethics com-
mittee and UK Home Office approval.
Single fibre preparation
Single fibres from mouse EDL or soleus muscle were iso-
lated and cultured in order to obtain satellite cells as
described recently [14]. Briefly, muscle tissue was dis-
sected from mice of appropriate age and genotype in a
manner that minimised injury, stretch, or other stress fac-
tors on the fibres. Connective tissue was removed by incu-
bation in DMEM (Gibco, Paisley, UK) with 0.2%
collagenase type I at 35°C for 1 h. Fibres were liberated by
trituration in DMEM medium with Pasteur pipettes of dif-
ferent pore sizes. Fibres were fixed in 4% PFA, or placed in
isolated wells of 8-well Permanox™ chamber slides (Nal-
geNunc International, Rochester, USA), coated with
Matrigel (1 mg/ml in DMEM, BD Biosciences, Oxford,
UK) for satellite cell cultivation and
immunocytochemistry.
Satellite cell cultivation
Single fibres were allowed to adhere to the Matrigel matrix
(3–5 mins), before adding 300 µl of plating medium
(10% horse serum, HS (Gibco), 0.5% Chick Embryo
Extract, CEE (Sera Laboratories International Ltd., Craw-
ley, UK), in DMEM with 1% streptomycin/penicillin and
2% L-glutamine) and incubation in a humidified environ-
ment at 37°C and 5% CO2. After 3 days incubation to
allow satellite cells to migrate off the fibre onto the
Matrigel substrate, fibres were removed from the cham-
bers and medium was replaced by proliferation medium
(PM; 20% fetal calf serum, FCS, 10% HS, 2% CEE in
DMEM). After further two days, PM was replaced by dif-
ferentiation medium (DM ; 2% FCS in DMEM) and cells
were allowed to differentiate for 2 or 5 days. Three days
after plating and again after two days in proliferation
medium, the total number of cells was analysed for each
single fibre culture. To check for the influence of IGF-1
treatment on differentiation efficiency of satellite cells,
PM, DM, or both were supplemented with 100 ng/ml of
recombinant R3-IGF-1 (Sigma, Deisenhofen, Germany).
Immunocytochemistry
Slides were rinsed in PBS, fixed in cold methanol, blocked
in 5% horse serum in PBS, and incubated with mAb
against desmin (1/500, clone no. DE-U-10, IgG1; Sigma)
and MyHC (1/10, A4.1025, IgG2a; [16]). Primary anti-
bodies were successively detected with rat anti-mouse
IgG1 (1:1,000; Serotec, Oxford, UK), FITC-conjugated
goat anti-mouse IgG2a (1:100; Serotec, Oxford, UK), and
Cy3-conjugated donkey anti-rat IgG (1:100; Jackson,
USA). In the last antibody incubation, the DNA dye DAPI
was added. Cells were washed, re-fixed in cold methanol
and mounted with antifading agent. Cell differentiation
was analysed by monitoring 10 randomly-selected fields
of view equivalent to a total area of 5.45 mm2 of each
chamber, representing approximately 15% of the area of
each chamber. Differentiation efficiency (labelled 'Myob-
last differentiation') was determined as the ratio of nuclei
in myosin heavy chain positive (MyHC+) myocytes and/
or myotubes divided by the total number of nuclei in
desmin-expressing cells (desmin+ cells). Data presented
reflect means and standard deviation of fibres from each
of ≥  4 animals unless otherwise stated. Cultures from ≥  30
fibres were analysed in each case.
Results
A sensitive assay for satellite cell differentiation
Mice wild type or carrying one or two null alleles at the
myoD locus were used to establish an in vitro culture sys-
tem to measure the differentiation potential of satellite
cells in culture. In agreement with published data [17],
satellite cells from single EDL muscle fibres from wildtype
or heterozygous myoD+/- animals showed high levels of
differentiation, as assayed by the fraction of desmin+ myo-
genic cells that express MyHC, whereas satellite cells from
myoD deficient animals often failed to differentiate (Fig.
1A,B). Satellite cells of myoD wildtype mice (myoD+/+) dis-
played efficient differentiation (80% ± 3) within 2 days of
growth factor removal. Comparable numbers of satellite
cells from myoD+/- EDL muscles differentiated terminally
(75% ± 14), whereas cells obtained from myoD-/- muscle
fibres almost completely failed to differentiate (3% ± 1).
Thus, single fibre cultures can efficiently quantify myob-
last differentiation.
We checked that the myogenic cell yield and proliferation
of satellite cells did not differ between myoD+/+, myoD+/-,
and  myoD-/- fibres (Fig. 1C). During the 2 days in PM
around a 12- to 14-fold increase in cell numbers occurred,BMC Musculoskeletal Disorders 2005, 6:15 http://www.biomedcentral.com/1471-2474/6/15
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indicating an approximately 12 hour doubling time, inde-
pendent of genotype.
The presence of non-myogenic cells and/or total cell den-
sity might affect myogenic differentiation efficiency.
Therefore, we used desmin expression to discriminate
between myogenic and non-myogenic cells. Differentia-
tion efficiency in wells with different numbers of desmin
positive (desmin+) or desmin negative (desmin-) cells for
all cultures of myoD+/+,  myoD+/, and myoD-/- fibres was
compared (Fig. 1D). No effect of desmin- cells in the cul-
tures was detected on the differentiation potential of the
A method to quantitate satellite cell differentiation Figure 1
A method to quantitate satellite cell differentiation. Single fibres from EDL muscles of 2 month old mice were isolated 
and cultured for five days, switched to differentiation medium for two days and the fraction of desmin-positive (desmin+) cells 
expressing myosin heavy chain determined by immunofluorescence microscopy. A: Satellite cell cultures from myoD hetero-
zygous (myoD+/-) and homozygous null (myoD-/-) animals. Essentially all cells (blue nuclei: DAPI) express desmin (red: Cy3) in 
both genotypes, but note the lack of multinucleate myotubes and cells expressing MyHC (green: FITC) in the myoD-/-. B-D: 
Quantification of satellite cell-derived myoblast growth and differentiation by genotype. Error bar = SD. Numbers above col-
umns indicate number of wells counted (1 fibre/well) from 4 animals of myoD+/+, myoD+/-, and myoD-/- genotype, respectively. B: 
Differentiation of myoD-/- myoblasts is poor compared to littermates. C: Increase in cell number after the switch from plating 
to proliferation medium is independent from the genotype of the animals. myoD+/+, myoD+/- and myoD-/- cells proliferate to the 
same extent. D: The fraction of differentiated myogenic cells is unaffected by either the number of myogenic desmin+ cells or 
the number of non-myogenic desmin- cells in each well. In all genotypes (myoD+/+, myoD+/-, and myoD-/-) all fibres yielded myo-
genic cells.
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myogenic cells. On average, there were less than 11% non-
myogenic cells in any cultures from mice of any genotype.
Similarly, differentiation efficiency did not correlate with
the density of either total cells or desmin+ cells; satellite
cells are capable of differentiating (expressing MyHC)
independently of cell fusion. Therefore, in this culture sys-
tem, density of neither myogenic cells nor non-myogenic
cells has a detectable influence on differentiation
efficiency.
Differentiation potential of satellite cells from PMP22 
transgenic mice
To test whether reduced muscle motility, altered innerva-
tion, or fibre atrophy/regrowth might trigger satellite cell
changes in some individuals, we examined PMP22 C22
transgenic mice that all show signs of disease, but have a
heterogeneous progression. Mouse models have demon-
strated that excess PMP22 protein in Schwann cells leads
to repeated focal demyelination lesions in peripheral
nerves, decreased conduction velocity, and a muscle his-
tology characteristic of partial denervation, just as in
HMSN1A [13]. Histological analysis of sections of soleus
muscles revealed that in some individual animals signs of
dramatic fibre atrophy and/or regrowth are present (Fig.
2A). In addition, significant changes in fibre type occur, as
revealed by MyHC isoform expression. In other individu-
als, however, the alteration in muscle fibre size profile and
type was less marked (data not shown). To clarify whether
phenotypic variation is reflected in diversity of satellite
cell behaviour, we analysed satellite cells of PMP22 C22
transgenic mice at several ages. However, no significant
variation in satellite cell differentiation efficiency was
observed at any age examined (Fig. 2B). Again, no influ-
ence of myogenic or non-myogenic cell density on differ-
entiation was observed (data not shown). Little inter-
animal variation was observed, unlike the case of mdx ani-
mals (see below). Thus, PMP22 mice show no loss of sat-
ellite cell function.
Differentiation potential of satellite cells of mdx mice
To test whether satellite cells from EDL muscles of mdx
mice display a defect in differentiation, we compared sin-
gle fibre cultures of mdx with age-matched control ani-
mals, on the same genetic background, C57BL/10. In fibre
cultures from 2 month old control and mdx animals dif-
ferentiation was 87% ± 3 and 80% ± 5, respectively (Fig.
3A–C). Thus, the early phase of significant degeneration/
regeneration in mdx mice led to no detectable change in
satellite cell differentiation.
We have observed decline in differentiation capacity as
satellite cells age in regenerating muscle [14]. In the
present study, satellite cells from control C57BL/10 mice
yield high levels of differentiation at all ages examined
with only a slight and not significant decrease with age
(87% ± 3, 84% ± 5, and 82% ± 6 in fibres from 2, 6, and
12 month old mice, respectively; Fig. 3A). Similar experi-
ments were performed for mdx animals of corresponding
ages. Across all fibres from all mdx animals, no significant
difference in differentiation in comparison to wildtype
animals was observed. Mean differentiation efficiency was
80% (± 5) at 2 months old, 66% (± 15) at 6 months old,
and 72% (± 20) at 12 months old mdx animals. However,
as indicated by the high standard deviation, the variance
in differentiation was extremely high in older animals.
We investigated the reason for the higher variance in dif-
ferentiation of 6 and 12 month mdx cultures. Whereas
numbers of cells per well and desmin+ or desmin- cell den-
sity showed no apparent contribution to variance, animal
to animal differences were striking. Many individual mdx
mice yielded satellite cells capable of differentiating as
well as age-matched controls. However, some individual
animals yielded particularly poorly differentiating cells
(Fig. 3B). This variation could not be accounted for by day
to day variation in culture conditions because age-
matched mdx and wild type animals were always prepared
in parallel. There was no indication of correlation with
sex, health status, housing conditions, or season,
although numbers of animals were too low to eliminate
any of these variables with high confidence.
Differentiation defect of affected mdx satellite cells can 
be overcome by prolonged differentiation time
Poor satellite cell differentiation in some older mdx mice
could reflect a permanent block or simply a delay. We
therefore examined differentiation rate in satellite cells
from older animals that showed poor differentiation. Sin-
gle fibre cultures were allowed to differentiate in low-
serum medium for 5 days (5d diff) instead of the normal
2 days (2d diff) employed in all other experiments. Pro-
longed differentiation did not significantly enhance dif-
ferentiation of control cultures (78% ± 6 and 83% ± 5
after 2 and 5 days, respectively). However, a prolonged
differentiation period did rescue differentiation of mdx
cells to levels indistinguishable from control 5 day cul-
tures (Fig. 4). A significant increase in differentiation
capacity from 63% ± 6 to 87% ± 2 in mdx  mice was
observed. We conclude from this result that satellite cells
from some mdx mice differentiate less efficiently in our
experimental system as reflected by a slower rate of MyHC
accumulation.
IGF-1 treatment does not influence the differentiation of 
satellite cells in vitro
IGF-1 signals have been shown to enhance both prolifer-
ation and differentiation of satellite cells [18]. To begin to
define the nature of the emerging satellite cell defect in
muscles of some mdx mice, we exposed satellite cells from
6 month old control or poorly-differentiating mdx ani-BMC Musculoskeletal Disorders 2005, 6:15 http://www.biomedcentral.com/1471-2474/6/15
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mals to IGF-1 (100 ng/ml) either in the proliferation
phase, the differentiation phase or both (P+IGF, D+IGF,
P+IGF D+IGF, respectively; Fig. 5). Controls were culti-
vated for the same time periods in the appropriate
medium without IGF-1 (P+ D+). No significant effect of
the IGF-1 treatment on the terminal differentiation of sat-
ellite cells was observed in any of the culture stages (Fig.
5A). Thus, IGF-1 level is not rate limiting for differentia-
tion of mdx  cultures that show reduced differentiation
rate. Neither can IGF-1 promote differentiation of the
undifferentiated ~20% of desmin+  cells in control
cultures.
As controls, we checked that the proportion of myogenic,
desmin+ cells in the cultures was not altered significantly
by IGF-1 treatment in relation to total cell number in
either control or mdx. However, the fraction of non-myo-
genic cells was over three times greater in mdx (58% ± 6)
than in controls (16% +/- 5), independent of IGF-1 treat-
ment (Fig. 5B). As found in the experiments above,
despite this difference in non-myogenic cell numbers, dif-
ferentiation efficiency was comparable between mdx and
controls (Fig. 5A).
Differentiation of satellite cells of the HMSN1A mouse model PMP22 C22 at three ages Figure 2
Differentiation of satellite cells of the HMSN1A mouse model PMP22 C22 at three ages. A. Variation in soleus 
muscle cryosections reacted for slow MyHC reveals variable pathology of individual PMP22 C22 mice. Note fibre atrophy 
(arrowheads) and large, hypertrophied fibres in the middle compared to the right panel. B. Satellite cells from single fibre cul-
ture of PMP22 C22 and littermate controls were analysed for cell yield, proliferation and terminal differentiation. No significant 
differences were observed.
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Discussion
Satellite cells are normally quiescent cells that reside
under the basal lamina of muscle fibres. Under conditions
of growth and repair, satellite cells become activated and
begin a coordinated myogenic program: they initially
proliferate and express a range of myogenic genes, includ-
ing desmin, before aligning and fusing to form terminally
differentiated multinucleate syncitia that organise and
express the contractile apparatus, which includes the
MyHC proteins. We have shown recently that, in MSVski
transgenic mice, satellite cell differentiation in vitro was
influenced by the age of the study animals and showed a
progressive decline with age [14]. This effect was much
less obvious in wildtype control animals. Therefore, we
concluded that a satellite cell differentiation defect devel-
oped in MSVski mice. We speculated that the defect might
be caused by continual degeneration/repair apparent in
hypertrophic MSVski mice and that the changes in satellite
cells might underlie the worsening of the muscle patho-
logical profile with age. The mdx mouse model of human
DMD displays a hypertrophy phenotype in the skeletal
musculature reminiscent of MSVski mice. Similarly, DMD
patients initially show a mild phenotype that gradually
progresses throughout the lifespan, manifesting as muscle
Differentiation of satellite cells of control and mdx mice of different ages in vitro Figure 3
Differentiation of satellite cells of control and mdx mice of different ages in vitro. A. Box and whisker plot: The box 
extends from the 25th percentile to the 75th percentile between all animals of one age, with a horizontal line at the median 
(50th percentile). Whiskers show the range of the data. B. Mean differentiation for each individual animal shows heterogeneity 
between mdx animals. Individuals showing poor differentiation (8 in total) are significantly more common in mdx (X2, P = 
0.0076). C. Satellite cell cultures from single fibres of 12 month old control C57BL/10ScSn and mdx animals showing good dif-
ferentiation in each case. Blue nuclei: DAPI; desmin: red, Cy3; MyHC: green, FITC in both genotypes.
B A
C
control mdx
2m 6m 12m 2m 6m 12m
0
25
50
75
100
control mdx
M
y
o
b
l
a
s
t
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
(
%
)
2m 6m 12m 2m 6m 12m
0
25
50
75
100
control mdx
M
y
o
b
l
a
s
t
d
i
f
f
e
r
e
n
t
i
a
t
i
o
n
(
%
)BMC Musculoskeletal Disorders 2005, 6:15 http://www.biomedcentral.com/1471-2474/6/15
Page 8 of 13
(page number not for citation purposes)
loss and fibrosis which culminates in death from respira-
tory or cardiac failure. As the progression of DMD is not
understood and because of similarities between DMD/
mdx  pathology and the MSVski  animal phenotype we
hypothesised that progressive defect in the differentiation
potential of satellite cells might contribute to the patho-
logic mechanism of the debilitating human disease.
We find that satellite-derived cells from ageing mdx mice
are, in general, capable of differentiating to the same
degree as satellite-derived cells from control animals. We
did not assess satellite-derived cells that remained physi-
cally juxtaposed to the explanted fibre because such cells
could display different behaviour(s) due to variations in
the fibre integrity or its surrounding matrix. We chose to
measure differentiation as the fraction of desmin-express-
ing cells co-expressing MyHC rather than fusion for sev-
eral reasons. Firstly, without using assays that detect
syncitia [19], there is no way of clearly ascertaining
whether two cells are truly fused or closely apposed. Sec-
ondly, mononucleate cells are capable of terminally dif-
ferentiating and expressing MyHC; such cells would be
missed if assessing fusion. Although we can not eliminate
the possibility that the mdx condition leads to an altera-
tion in the cells that express desmin, our study provides
evidence against this view. First, yields of desmin+ cells are
similar between mdx and control. Second, the prolifera-
tion rate of desmin+ cells appears similar between mdx and
Prolongation of differentiation rescues the satellite cell differentiation defect Figure 4
Prolongation of differentiation rescues the satellite cell differentiation defect. Satellite cells of 6 months old mdx or 
control animals were plated and allowed to proliferate as described in Materials and Methods and then cultivated either for 2 
days (2d diff) or for 5 days (5d diff) in differentiation medium. Prolongation of the differentiation period to 5 days enhances dif-
ferentiation efficiency (* P < 0.0028) of affected mdx satellite cells to the level observed in controls.
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control. Third, and as discussed further below, although
numbers of desmin- cells are increased in mdx cultures the
increase is similar both before and after the differentiation
phase suggesting that interconversion of desmin-  and
desmin+ cells is not a significant factor in our experiments.
Overall, it is unlikely that a defect in differentiation of sat-
ellite-derived cells is a major contributor to disease pro-
gression in mdx mice.
Despite this lack of significant change in overall differen-
tiation capacity, satellite-derived cells from some individ-
ual older mdx  animals displayed lower differentiation
efficiencies than those from other mdx  animals of the
same age. Age- and background genotype-matched con-
trol mice, young mdx mice, and mice with severe muscle
weakness due to the PMP22 transgene did not show this
variation. We were unable to correlate this effect to any
factor analysed. All animals were held under similar
conditions. We consciously used both genders and ana-
lysed data in combination of both sexes and separately.
We conducted additional experiments using increased or
decreased collagenase type I incubation times as well as a
more severe collagenase type II digestion to determine if
variations in satellite cell activation or yield, basal lamina
digestion, or fibre damage could affect differentiation
potential, but found no differences (data not shown).
Similarly, we performed dilution cloning of satellite cells
to assess the effects of proliferation rate on satellite cells
IGF-1 treatment fails to rescue differentiation of satellite cells in culture Figure 5
IGF-1 treatment fails to rescue differentiation of satellite cells in culture. Satellite cells from control or mdx animals 
at the age of 6 months were treated with IGF-1 (100 ng/ml medium) during either proliferation (P+IGF), differentiation 
(D+IGF), both (P+IGF D+IGF), or neither (P+D+, control). A. Differentiation was unaltered by IGF-1 addition. B. Non-myo-
genic cells are more abundant in mdx than control single fibre cultures.
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and whereas we observed heterogeneity of proliferation
rates amongst satellite cells grown from single cells, we
again found no ultimate difference in differentiation effi-
ciency (data not shown). For those reasons we can not
explain the inter-animal variation of mdx results by differ-
ences in the experimental design or genetic background of
the animal. We speculate that uncontrolled environmen-
tal effects or epigenetic factors affecting other genes in the
mdx background explain the variation. It is striking that
fibres yielding poorly-differentiating cells are numerous
in affected individuals, but nevertheless, some fibres yield
cells differentiating as well in controls. This emphasises
that relatively heritable heterogeneity in myogenic cells
must exist in mdx mice and demands elucidation. Moreo-
ver, we can not eliminate the possibility that the mdx indi-
viduals showing poor differentiation in our assay would
have undergone a worse progression of disease in later
life. Additionally, we cannot exclude the possibility that
very subtle differences in differentiation behaviour were
not detected in our assay system as we have utilized
matrigel, a matrix in which growth factors are abundant.
Thus, small variations might have been masked that only
would be detectable at the application of collagen or gel-
atine matrices.
As shown by others [20] and in this report, non-myogenic
cells, probably fibroblasts, can be obtained from single
fibre cultures and are more abundant in mdx  samples
compared with C57BL/10 controls. These cells probably
reside on the fibre surface and migrate away from the fibre
onto the substrate as do satellite-derived cells. In vivo,
these cells may mediate the fibrotic response to fibre
degeneration and could potentially secrete factors such as
TGF-β  that have been shown to interfere with satellite cell
differentiation [21]. We analysed the proportion of non-
myogenic cells in the cultures and whether they influ-
enced the efficiency of differentiation of myogenic cells.
We were unable to find a correlation between the contam-
ination of the satellite cell culture with desmin- non-myo-
genic cells and the differentiation efficiency of the
myogenic cells in the same culture well. This confirms
what we have observed in wild type, MSVski, PMP22, and
myoD null situations [14]. There was also no difference in
desmin- cell levels between mice showing poor or normal
differentiation. Thus, at least in mdx animals up to one
year of age, no correlation of fibrosis with poor myoblast
differentiation is apparent.
Differentiation is delayed, not inhibited in some mdx mice
We found that satellite-derived cells from mdx mice show-
ing poor differentiation after two days differentiation,
recovered and differentiated as well as controls after three
further days in differentiation conditions. No morpholog-
ical differences in the nature of the differentiated cells
were detected at this stage. Thus, the reduction in differen-
tiation observed in some mdx  animals is most simply
explained as a reduced rate of differentiation. If such a
decrease in differentiation rate occurs in vivo, it could have
serious consequences for muscle repair, which may
require rapid satellite cell mobilisation and can occur
within a few days [22].
IGF-1 treatment has been shown to enhance the efficiency
of differentiation of satellite-derived myoblasts and this
has been suggested to mediate an autocrine loop triggered
by myogenin expression [23]. However, IGF-1 treatment
of poorly-differentiating mdx satellite-derived cells did not
enhance their differentiation rate. Moreover, although it
has been reported that IGF-treatment of wildtype myo-
genic cells leads to enhanced proliferation [24,25], in our
experimental conditions using recombinant R3 IGF-I we
were not able to confirm those findings.
Functional impairment in HMSN1A model mice is not 
accompanied by satellite cell changes
A rodent model for the progressive human neuropathy
HMSN1A is the PMP22 C22 transgenic mouse that har-
bours seven copies of the human PMP22  gene in its
genome. These animals manifest symptoms similar to
human HMSN1A patients including demyelination of
Schwann cells and, with later age, progressive skeletal
muscle weakness caused by poor innervation [13].
Examination of postural soleus muscle from such mice
revealed a heterogeneous progression of muscle pathol-
ogy. Some animals showed severe signs of atrophic fibres
and changes in fibre type proportion, probably caused by
altered electrical activity consequent to slowed nerve con-
duction. Other individuals, which also showed poor
movement, had relatively healthy muscle histology. A
cohort of affected PMP22 C22 mice with altered gait were
analysed by single fibre culture and revealed no changes
in number, proliferation, or differentiation of desmin+
cells compared to age- and genetic background-matched
controls. Thus, the HMSN1A model mice show a strong
phenotype which seems to involve muscle fibre atrophy
after demyelination of its innervating motorneuron fol-
lowed by satellite cell recruitment in the regrowth phase
after myelination is restored. However, these processes
have no observable effect on mononucleate cells in single
fibre cultures.
Differentiation defect in satellite cells lacking myoD
There has been controversy surrounding the role of the
myogenic transcription factor MyoD in satellite cell differ-
entiation. Early reports suggested the myoD null muscle
regenerated poorly and that myoblasts from young myoD
null mice differentiated poorly in vitro [17,26]. However,
a recent study showed the myoD null satellite cells can dif-
ferentiate efficiently under some circumstances [27]. In
our single EDL muscle fibre cultures, satellite-derivedBMC Musculoskeletal Disorders 2005, 6:15 http://www.biomedcentral.com/1471-2474/6/15
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myoblasts from wild type or heterozygous myoD+/- mice
differentiate efficiently. In contrast, few desmin-express-
ing satellite-derived cells from myoD deficient mice were
able express MyHC within two days. Given the rapid
repair of entire muscles within several days of toxin-
induced injury [22], the differentiation delay in myoD null
would have severe consequences in wild populations if a
similar delay occurred in any in vivo setting.
An issue not addressed directly by our study is the rela-
tionship of the assayed population of desmin-expressing
cells from wild type to that from myoD null animals. For
example, lack of myoD might cause a change in the num-
bers of cells expressing desmin. We think this unlikely
because the yield of desmin+  cells, and the ratio of
desmin+ to desmin- cells, were unaltered in our single fibre
cultures, irrespective of myoD  genotype. Whatever the
case, our experiment shows that lack of myoD leads to sub-
stantial reduction in the capacity of muscle fibre-associ-
ated migratory proliferative cells to undergo terminal
differentiation into myotubes.
Conclusion
As there appears to be no distinct differentiation defect in
the satellite cells of mdx mice, at least by our assay, the
cause of progressive muscle loss in the diseased state
remains unclear. The differentiation potential of satellite
cells has generated contradictory results in several early
studies, where differentiation was measured as myoblast
fusion in primary cultures (reviewed in [28,29]). One
study concluded no differentiation defect [4], whereas Jas-
min and colleagues found a reduced differentiative capac-
ity in myoblasts derived from DMD patients [30]. A very
recent publication by Schaefer et al. also revealed hetero-
geneity in the number of satellite cells between individual
mdx and C57 animals. The authors observed that this het-
erogeneity did not correlate with age, gender, or degree of
degeneration, but possibly reflected additional genetic
factors that influence the maintenance of the satellite cell
pool [31].
Altered myoblast number appears not to explain disease
progression. Some studies find an increase in the number
of satellite cells associated with DMD/mdx muscle fibres
([32-35] and our unpublished observations), although
others observe little change [7]. Thus loss of available cells
for repair is unlikely to cause disease progression. Despite
reports of increased cell death in DMD/mdx myoblasts
[36-38], we found no evidence of differential apoptosis
between control and mdx. It has also been suggested that
decreased proliferative potential and early senescence of
satellite cells is the primary cause of disease progression
[3,39]. One group measured this limitation as an acceler-
ated age-related shortening of satellite cell telomere
length [40], a result contradicted by another study using a
similar assay [41]. We observed no change in proliferative
capacity of mdx satellite-derived cells. These findings sug-
gest that the proliferative potential of satellite cells or their
ability to self renew is not compromised; the number of
satellite cells remains higher than controls throughout the
lifespan of the animals ([32]; our observations).
In summary, our study is the first to provide data on the
differentiation efficiency of satellite cells in older mdx and
PMP22 C22 mice. We found that, generally, the age of the
individual animal had little impact on the differentiation
of satellite cells. The pathological processes in muscle of
mice with mdx or PMP22 C22 genotype are not necessarily
accompanied by defects in satellite cell differentiation.
However, in some mdx individuals, satellite cell differen-
tiation is impaired after the age of two months, in a man-
ner akin to that we observed in MSVski  hypertrophic
muscle pathology [14]. It seems clear that there is hetero-
geneity in the pathology of muscle in various animal
models of human disease, probably due to epigenetic/
environmental contributions. It remains to be further
investigated what causes cases of poor differentiation and
whether this impaired differentiation of satellite cells
enhances deterioration of the physical condition of the
individual.
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